Profile

New User

New to Graphy Publications? Create an account to get started today.

Registered Users

Have an account? Sign in now.

How to Cite | Author Information | Publication History
International Journal of Community & Family Medicine Volume 1 (2016), Article ID 1:IJCFM-107, 3 pages
https://doi.org/10.15344/2456-3498/2016/107
Mini Review
Brain Natriuretic Peptide in Cirrhosis

Ana Lanca Bastiancic1* and Sandra Milic2

1Department of Cardiology, Thalassotherapia Opatija, Clinic for treatment, rehabilitation and prevention of cardiovascular disease, Opatija,Croatia
2Department of Gastroenterology, University of Rijeka School of Medicine, University Hospital Centre Rijeka, Rijeka, Croatia
Dr. Ana Lanca Bastiancic, Department of Cardiology, Thalassotherapia Opatija, Clinic for treatment, rehabilitation and prevention of cardiovascular disease, Opatija, Croatia, Tel: +385958621080; E-mail: analanca22@gmail.com
21 January 2016; 23 April 2016; 25 April 2016
Bastiancic AL, Milic S (2016) Brain Natriuretic Peptide in Cirrhosis. Int J Community Fam Med 1: 107. doi: https://doi.org/10.15344/2456-3498/2016/107
© 2016 Bastiancic et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

References

  1. Maeda K, Tsutamoto T, Wada A, Hisanaga T, Kinoshita M, et al. (1998) Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J 135: 825-832 [CrossRef] [Google Scholar] [PubMed]
  2. Leite-Moreira AF (2006) Current perspectives in diastolic dysfunction and diastolic heart failure. Heart 92: 712-718 [CrossRef] [Google Scholar] [PubMed]
  3. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, et al. (2012) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 33: 1787-1847 [CrossRef] [Google Scholar] [PubMed]
  4. Abdeen Y, Sen P, Safdar S, Katapally R, Arqoob AA, et al. (2015) The usefulness of brain natriuretic peptide level in diagnosis and prognosis of patients admitted to critical care unit with shortness of breath. J Emerg Trauma Shock 8: 205-209 [CrossRef] [Google Scholar] [PubMed]
  5. Karmpaliotis D, Kirtane AJ, Ruisi CP, Polonsky T, Malhotra A, et al. (2007) Diagnostic and prognostic utility of brain natriuretic Peptide in subjects admitted to the ICU with hypoxic respiratory failure due to noncardiogenic and cardiogenic pulmonary edema. Chest 131: 964-971 [CrossRef] [Google Scholar] [PubMed]
  6. Omar AS, Ur Rahman M, Dhatt GS, Salami GO, Abuhasna S (2013) Dynamics of brain natriuretic peptide in critically ill patients with severe sepsis and septic shock. Saudi J Anaesth 7: 270-276 [CrossRef] [Google Scholar] [PubMed]
  7. Budweiser S, Luchner A, Jörres RA, Heinemann F, Hitzl AP, et al. (2007) NT-proBNP in chronic hypercapnic respiratory failure: A marker of disease severity, treatment effect and prognosis. Respir Med 101: 2003-2010 [CrossRef] [Google Scholar] [PubMed]
  8. Stolz D, Breidthardt T, Christ-Crain M, Bingisser R, Miedinger D, et al. (2008) Use of B-type natriuretic peptide in the risk stratification of acute exacerbations of COPD. Chest 133: 1088-1094 [CrossRef] [Google Scholar] [PubMed]
  9. Passino C, Poletti R, Fontana M, Vergaro G, Prontera C, et al. (2008) Clinical relevance of non-cardiac determinants of natriuretic peptide levels. Clin Chem Lab Med 46: 1515-1523 [CrossRef] [Google Scholar] [PubMed]
  10. Cowie MR, Jourdain P, Maisel A, Dahlstrom U, Follath F, et al. (2003) Clinical applications of B-type natriuretic peptide (BNP) testing. Eur Heart J 24: 1710-1718 [CrossRef] [Google Scholar] [PubMed]
  11. Daniels LB, Maisel AS (2007) Natriuretic peptides. J Am Coll Cardiol 50: 2357-2368 [CrossRef] [Google Scholar] [PubMed]
  12. Zhang C, Huang D, Shen D, Zhang L, Wang Y, et al. (2015) Brain Natriuretic Peptide as the long-term cause of mortality in patients with cardiovascular disease: a retrospective cohort study. Int J Clin Exp Med 8: 16364-16368 [Google Scholar] [PubMed]
  13. Laura Leto, Marzia Testa, Mauro Feola (2015) Correlation between B-Type Natriuretic Peptide and Functional/Cognitive Parameters in Discharged Congestive Heart Failure Patients. Int J Endocrinol : 239136 [CrossRef] [Google Scholar]
  14. Chang HR, Hsieh JC, Hsu BG, Wang LY, Chen MY, et al. (2013) Inverse association of N-terminal pro-B-type natriuretic peptide with metabolic syndrome in patients with congestive heart failure. PLoS One 8: e79096 [CrossRef] [Google Scholar] [PubMed]
  15. Geske JB, McKie PM, Ommen SR, Sorajja P (2013) B-type natriuretic peptide and survival in hypertrophic cardiomyopathy. J Am Coll Cardiol 61: 2456-2460 [CrossRef] [Google Scholar] [PubMed]
  16. Mocarzel L, Lanzieri P, Nascimento J, Peixoto C, Ribeiro M, et al. (2015) Hepatorenal syndrome with cirrhotic cardiomyopathy: case report and literature review. Case Reports Hepatol 2015: 573513 [CrossRef] [Google Scholar] [PubMed]
  17. Zardi EM, Abbate A, Zardi DM, Dobrina A, Margiotta D, et al. (2010) Cirrhotic cardiomyopathy. J Am Coll Cardiol 56: 539-549 [CrossRef] [Google Scholar] [PubMed]
  18. Páll A, Czifra A, Vitális Z, Papp M, Paragh G, et al. (2014) Pathophysiological and clinical approach to cirrhotic cardiomyopathy. J Gastrointestin Liver Dis 23: 301-310 [CrossRef] [Google Scholar] [PubMed]
  19. Marchetta S, Delwaide J, Lancellotti R (2015) [Cirrhotic cardiomyopathy: a brief overview]. Rev Med Liege 70: 86-91 [Google Scholar] [PubMed]
  20. Licata A, Corrao S, Petta S, Genco C, Cardillo M, et al. (2013) NT Pro BNP Plasma Level and Atrial Volume Are Linked to the Severity of Liver Cirrhosis. PLoS One 8: e68364 [CrossRef] [Google Scholar] [PubMed]
  21. Wiese S, Hove JD, Bendtsen F, Møller S (2013) Cirrhotic cardiomyopathy: pathogenesis and clinical relevance. Nature Reviews Gastroenterology & Hepatology 11: 177-186 [CrossRef] [Google Scholar] [PubMed]
  22. Møller S, Hove JD, Dixen U, Bendtsen F (2013) New insights into cirrhotic cardiomyopathy. Int J Cardiol 167: 1101-1108 [CrossRef] [Google Scholar] [PubMed]
  23. Chayanupatkul M, Liangpunsakul S (2014) Cirrhotic cardiomyopathy: review of pathophysiology and treatment. Hepatol Int 8: 308-315 [CrossRef] [Google Scholar] [PubMed]
  24. Padillo J, Rioja P, Muñoz-Villanueva MC, Vallejo JA, Ciria R, et al. (2010) BNP as marker of heart dysfunction in patients with liver cirrhosis. Eur J Gastroenterol Hepatol 22: 1331-1336 [CrossRef] [Google Scholar] [PubMed]
  25. Henriksen JH, Gøtze JP, Fuglsang S, Christensen E, Bendtsen F, et al. (2003) Increased circulating pro-brain natriuretic peptide (proBNP) and brain natriuretic peptide (BNP) in patients with cirrhosis: relation to cardiovascular dysfunction and severity of disease. Gut 52: 1511-1517 [CrossRef] [Google Scholar] [PubMed]
  26. Shi LY, Jin R, Lin CJ, Wu JS, Chen XW, et al. (2015) B-type natriuretic peptide and cirrhosis progression. Genet Mol Res 14: 5188-5196 [CrossRef] [Google Scholar] [PubMed]
  27. Pimenta J, Paulo C, Gomes A, Silva S, Rocha-Gonçalves F, et al. (2010) B-type natriuretic peptide is related to cardiac function and prognosis in hospitalized patients with decompensated cirrhosis. Liver Int 30: 1059- 1066 [CrossRef] [Google Scholar] [PubMed]
  28. Woo JJ, Koh YY, Kim HJ, Chung JW, Chang KS, et al. (2008) N-terminal pro B-type natriuretic peptide and the evaluation of cardiac dysfunction and severity of disease in cirrhotic patients. Yonsei Med J 49: 625-631 [CrossRef] [Google Scholar] [PubMed]
Best viewed in Mozilla Firefox, Google Chrome, Safari, Above IE 9.0 version
Privacy Policy | Copyright & Permissions
Copyright © 2013-2024 Graphy Publications, All Rights Reserved.